Another independent validation study using data from the Netherlands Cancer Registry reported a reliable prediction of 5-year overall survival for patients estrogen receptor–positive cancer but an underestimation of overall survival (ie, overestimation of mortality) for patients with estrogen receptor–negative cancer (7). Here, ESR1 is linked to cancer.